Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25282966 | 0.84 | CFD (0.44) | KDM4EALDH1A1GRIN2BCFDMEN1 | |
| SCHEMBL29774878 | 0.84 | ICMT (0.44) | KDM4EALDH1A1GRIN2BCFD | |
| SCHEMBL18554883 | 0.84 | ICMT (0.44) | KDM4EALDH1A1GRIN2BCFD | |
| SCHEMBL29841188 | 0.82 | TP53 (0.39) | KDM4EALDH1A1SYKMEN1KMT2A | |
| SCHEMBL18555010 | 0.82 | TP53 (0.39) | KDM4EALDH1A1SYKMEN1KMT2A | |
| SCHEMBL18591259 | 0.79 | SMN1; SMN2 (0.44) | SYKMEN1KMT2A | |
| SCHEMBL18554870 | 0.77 | CA9 (0.41) | KDM4EALDH1A1GRIN2BCFD | |
| SCHEMBL18591225 | 0.75 | ICMT (0.43) | KDM4EALDH1A1GRIN2BDYRK1AWNT1 | |
| SCHEMBL29545307 | 0.75 | PKM (0.39) | KDM4EALDH1A1SYKCFDGPR119 | |
| SCHEMBL17024802 | 0.75 | PKM (0.39) | KDM4EALDH1A1SYKCFDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | KDM4E 4387/4885ALDH1A1 1682/4885GRIN2B 3244/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | KDM4E 4286/4885ALDH1A1 1847/4885GRIN2B 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.